Calithera Biosciences Inc. (NASDAQ:CALA) shares hit a new 52-week low on Monday . The stock traded as low as $3.55 and last traded at $3.55, with a volume of 209,140 shares. The stock had previously closed at $3.63.

Several brokerages have weighed in on CALA. Zacks Investment Research lowered Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Calithera Biosciences in a research report on Wednesday, June 8th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $10.48.

The company’s market cap is $64.07 million. The company’s 50-day moving average price is $4.50 and its 200 day moving average price is $5.32.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by $0.05. On average, equities research analysts expect that Calithera Biosciences Inc. will post ($2.15) earnings per share for the current year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.